Literature DB >> 14739573

Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems.

Monette S Castillo1, Faith G Davis, Tanya Surawicz, Janet M Bruner, Sandra Bigner, Stephen Coons, Darell D Bigner.   

Abstract

High-quality cancer registry data are essential for assessing trends in incidence rates. This study evaluated the consistency of brain tumor surveillance data using a random sample of cases from the Connecticut Tumor Registry. Three neuropathologists independently and blindly reviewed tumor slides from 204 cases and a nosologist blindly reviewed and assigned International Classification of Diseases for Oncology (ICD-O) codes to 326 cases. For the pathology review, absolute concordance was as high as 81% for all primary brain tumors. Absolute concordance rates were high for nerve sheath (89%), meningioma (95%), and pituitary (95%) tumors. Rates were much lower for malignant tumors. ICD-O coding of malignant brain tumors is of relatively high quality with the exception of mixed gliomas and unspecified tumors. A high level of consistency for nonmalignant brain tumor diagnoses suggests that rates for these tumors, when actively reported to a surveillance system, can be of high quality. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 14739573     DOI: 10.1159/000073980

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  16 in total

1.  The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database.

Authors:  Panagiotis Kerezoudis; Anshit Goyal; Victor M Lu; Mohammed Ali Alvi; Mohamad Bydon; Sani H Kizilbash; Terry C Burns
Journal:  J Neurooncol       Date:  2019-12-24       Impact factor: 4.130

Review 2.  Chemotherapy wafers for high grade glioma.

Authors:  Michael G Hart; Robert Grant; Ruth Garside; Gabriel Rogers; Margaret Somerville; Ken Stein
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

3.  Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.

Authors:  Sara Hoffman; Jennifer M Propp; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

4.  Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study.

Authors:  Steven Hsu; Marisa Quattrone; Quinn Ostrom; Timothy C Ryken; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  J Neurosurg Spine       Date:  2011-03-11

5.  Determination of intra-axial brain tumors cellularity through the analysis of T2 Relaxation time of brain tumors before surgery using MATLAB software.

Authors:  Jamil Abdolmohammadi; Mohsen Shafiee; Fariborz Faeghi; Douman Arefan; Alireza Zali; Rouzbeh Motiei-Langroudi; Zahra Farshidfar; Ali Kiani Nazarlou; Ali Tavakkoli; Mohammad Yarham
Journal:  Electron Physician       Date:  2016-08-25

6.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

7.  Prognosis and patterns of care in elderly patients with glioma.

Authors:  Fabio M Iwamoto; Anne S Reiner; Lakshmi Nayak; Katherine S Panageas; Elena B Elkin; Lauren E Abrey
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

8.  Low-grade gliomas in older patients: a retrospective analysis of prognostic factors.

Authors:  Nader Pouratian; Melike Mut; Jay Jagannathan; M Beatriz Lopes; Mark E Shaffrey; David Schiff
Journal:  J Neurooncol       Date:  2008-08-06       Impact factor: 4.130

Review 9.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Ruth Garside; Gabriel Rogers; Ken Stein; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

10.  Incidence of first primary central nervous system tumors in California, 2001-2005.

Authors:  Monica Brown; Rudolph Schrot; Katrina Bauer; Deanna Letendre
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.